ASCT


Also found in: Acronyms.

autologous stem cell transplantation (ASCT)

a treatment for advanced or refractory solid tumors, such as neuroblastomas, lymphomas, and Ewing's sarcoma. Stem cells from the bone marrow or blood are withdrawn before high-dose irradiation or chemotherapy that destroys many of the remaining cells; afterwards the removed cells are reinfused to form a new population of blood cells.

ASCT

Abbreviation for:
allogeneic stem cell transplantation
American Society for Cytotechnology
Asylum Seeker Co-ordination Team (Medspeak-UK) 
autologous stem cell transplantation
References in periodicals archive ?
These patients typically receive induction therapy and high-dose chemotherapy with melphalan followed by ASCT.
CALGB 100104 was a phase III, controlled, double-blind, multi-centre study of 460 patients with newly diagnosed MM undergoing ASCT who received continuous daily treatment with Revlimid or placebo until relapse.
However, the pitfall of this systematic review was not analyzing long term FL outcomes, and the authors conclude that the choice of the regimen should be decided individually based on the need to avoid anthracycline cardiotoxicity in older patients or in young patients where salvage therapy followed by ASCT is planned in the future.
Following the ASCT and high-dose chemotherapy there was an improvement in motor functions, although mild numbness of the hands and feet continued.
Bone marrow examination done 12 weeks after ASCT showed no evidence of residual disease (Figure 3).
As instrucoes do ASCT sao enunciadas de forma dramatizada, finalizando com uma solicitacao dirigida a crianca: "Mostra-me e conta-me o que acontece agora".
In this era of novel agents, treatment varies depending on whether the patient is eligible for ASCT or not.
Bothell, WA, announced the US Food and Drug Administration (FDA) has granted accelerated approval ofAdcetris (brentuximab vedotin) for two indications: (1) the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the treatment of patients with systemic anaplastic large cell lymphoma (ALCL) after failure of at least one prior multi-agent chemotherapy regimen.
Repeat bone marrow biopsy performed 5 months after ASCT showed no evidence of residual monoclonal plasma cell population, and plasma IgD concentrations remained near 0.
Although high dose melphalan with ASCT is an effective therapy for systemic AL amyloidosis, it is associated with high mortality.
After the third treatment cycle patients who obtain a complete or partial response will receive high dose chemotherapy followed by ASCT.
The investigators concluded that patient-specific, organ dosimetry-based significant dose escalation with RIT was achieved with outpatient ASCT support.